Recommendations for Classification of Commercial LBA Kits for Biomarkers in Drug Development From the GCC for Bioanalysis

References

• Premkumar N , LowesS, JerseyJet al. Formation of a global contract research organization council for bioanalysis. Bioanalysis2(11), 1797–1800 (2010).
   PubMed Web of Science ®Google Scholar
• Breda N , GarofoloF, CruzCaturla Met al. The 3rd Global CRO Council for Bioanalysis at the International Reid Bioanalytical Forum. Bioanalysis3(24), 2721–2727 (2011).
   PubMed Web of Science ®Google Scholar
• Lowes S , JerseyJ, ShoupRet al. 4th Global CRO council for Bioanalysis: coadministered drugs stability, EMA/US FDA guidelines, 483s and carryover. Bioanalysis4(7), 763–768 (2012).
   PubMed Web of Science ®Google Scholar
• Nicholson R , LowesS, CruzCaturla Met al. 6th GCC focus on LBA: critical reagents, positive controls and reference standards; specificity for endogenous compounds; biomarkers; biosimilars. Bioanalysis4(19), 2335–2342 (2012).
   PubMed Web of Science ®Google Scholar
• Rocci M , LowesS, ShoupRet al. 7th GCC: use of incurred samples; fit-for-purpose validation; solution stability; electronic lab notebooks; hyperlipidemic matrix testing. Bioanalysis6(20), 2713–2720 (2014).
   PubMed Web of Science ®Google Scholar
• Bower J , FastD, GarofoloFet al. 8th GCC: consolidated feedback to US FDA on the 2013 draft FDA guidance on bioanalytical method validation. Bioanalysis6(22), 2957–2963 (2014).
   PubMed Web of Science ®Google Scholar
• Hayes R , LeLacheurR, DumontIet al. 9th GCC closed forum: CAPA in regulated bioanalysis; method robustness, biosimilars, preclinical method validation, endogenous biomarkers, whole blood stability, regulatory audit experiences and electronic laboratory note books. Bioanalysis8(6), 487–495 (2016).
   PubMed Web of Science ®Google Scholar
• Cape S , IslamR, NehlsCet al. The 10th GCC Closed Forum: rejected data, GCP in bioanalysis, extract stability, BAV, processed batch acceptance, matrix stability, critical reagents, ELN and data integrity and counteracting fraud. Bioanalysis9(7), 505–516 (2017).
   PubMed Web of Science ®Google Scholar
• Islam R , BriscoeC, BowerJet al. The 11th GCC Closed Forum: cumulative stability; matrix stability; immunogenicity assays; laboratory manuals; biosimilars; chiral methods; hybrid LBA/LCMS assays; fit-for-purpose validation; China Food and Drug Administration bioanalytical method validation. Bioanalysis10(7), 433–444 (2018).
   PubMed Web of Science ®Google Scholar
• Lowes S , JerseyJ, ShoupRet al. Recommendations on: internal standard criteria, stability, incurred sample reanalysis and recent 483s by the Global CRO Council for Bioanalysis. Bioanalysis3(12), 1323–1332 (2011).
   PubMed Web of Science ®Google Scholar
• Boterman M , DoigM, BredaMet al. Recommendations on the interpretation of the new EMA guideline on bioanalytical method validation by Global CRO Council for Bioanalysis (GCC). Bioanalysis4(6), 651–660 (2012).
   PubMed Web of Science ®Google Scholar
• Sangster T , MaltasJ, StruwePet al. Recommendations on ISR in multi-analyte assays, QA/bioanalytical consultants and GCP by Global CRO Council for Bioanalysis (GCC). Bioanalysis4(14), 1723–1730 (2012).
   PubMed Web of Science ®Google Scholar
• Lowes S , BotermanM, DoigMet al. Recommendations on bioanalytical method stability implications of co-administered and coformulated drugs by Global CRO Council for Bioanalysis (GCC). Bioanalysis4(17), 2117–2126 (2012).
   PubMed Web of Science ®Google Scholar
• Hougton R , GoutyD, AllinsonJet al. Recommendations on biomarker bioanalytical method validation by GCC. Bioanalysis4(20), 2439–2446 (2012).
   PubMed Web of Science ®Google Scholar
• Lowes S , LeLacheurR, ShoupRet al. Recommendations on incurred sample stability (ISS) by GCC. Bioanalysis6(18), 2385–2390 (2014).
   PubMed Web of Science ®Google Scholar
• Stevenson L , RichardsS, PillutlaRet al. 2018 White Paper in bioanalysis part 3: focus on flow cytometry, gene therapy, cut points and key clarifications on BAV. Bioanalysis10(24), 1973–2001 (2018).
   PubMed Web of Science ®Google Scholar
• Bowsher RR , NowatzkeW, SailstadJM, KhanMU. Application of commercial research-grade biomarker assays in drug development: is it time to create “pharmaceutical-grade” kits?Bioanalysis4(20), 2427–2430 (2012).
   PubMed Web of Science ®Google Scholar
• Islam R , KarS, IslamC, FarmenR. Adaptation of commercial biomarker kits and proposal for “drug development kits” to support bioanalysis: call for action. Bioanalysis10(12), 945–955 (2018).
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services, US FDA, Center for Drug Evaluation and Research, Center for Veterinary Medicine. Guidance for Industry, Bioanalytical Method Validation. MD, USA (2018).
   Google Scholar
• Piccoli SP , SauerJM, AmurS et al. Points to consider document: scientific and regulatory considerations for the analytical validation of assays used in the qualification of biomarkers in biological matrices. https://healthpolicy.duke.edu/sites/default/files/atoms/files/cpath_ptc_biomarker_qualification_assays_20170623.pdf
   Google Scholar
• Piccoli SP , GarofoloF. Biomarker assay validation. Bioanalysis10(12), 889–891 (2018).
   PubMed Web of Science ®Google Scholar
• Jani D , AllisonJ, BerishaFet al. Recommendations for use and fit-for-purpose validation of biomarker multiplex ligand binding assays in drug development. AAPS J.18(1), 1–14 (2015).
   PubMed Web of Science ®Google Scholar
• Lee JW , DevanarayanV, BarrettYCet al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm. Res.23(2), 312–328 (2006).
   PubMed Web of Science ®Google Scholar
• Amaravadi L , SongA, MylerHet al. 2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers. Bioanalysis7(24), 3107–3124 (2015).
   PubMed Web of Science ®Google Scholar
• Richards S , AmaravadiL, PillutlaRet al. 2016 White Paper on recent issues in bioanalysis: focus on biomarker assay validation (BAV). Bioanalysis8(23), 2475–2496 (2016).
   PubMed Web of Science ®Google Scholar
• Gupta S , RichardsS, AmaravadiLet al. 2017 White Paper on recent issues in bioanalysis: a global perspective on immunogenicity guidelines and biomarker assay performance. Bioanalysis9(24), 1967–1996 (2017).
   PubMed Web of Science ®Google Scholar
• Khan MU , BowsherRR, CameronMet al. Recommendations for adaptation and validation of commercial kits for biomarker quantification in drug development. Bioanalysis7(2), 229–242 (2015).
   PubMed Web of Science ®Google Scholar
• Arnold ME , BoothB, KingLet al. Workshop Report: crystal city VI-bioanalytical method validation for biomarkers. AAPS J.18(6), 1366–1372 (2016).
   PubMed Web of Science ®Google Scholar
• FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource. Silver Spring (MD), Food and Drug Administration (US); Bethesda (MD), National Institutes of Health (USA) (2016).
   Google Scholar
• Cowan K , AmaravadiL, CameronM. Recommendations for selection and characterization of protein biomarker assay calibrator material. AAPS J.19(6), 1550–1563 (2017).
   PubMed Web of Science ®Google Scholar
• O'Hara DM , TheobaldV, EganACet al. Ligand binding assays in the 21st century laboratory: recommendations for characterization and supply of critical reagents. AAPS J.14(2), 316–328 (2012).
   PubMed Web of Science ®Google Scholar
• Westgard JO , AronssonT, GrothT, DeVerdier CH. Combined Shewhart cusum control chart for improved quality control in clinical chemistry. Clin. Chem.23(10), 1881–1887 (1977).
   PubMed Web of Science ®Google Scholar
• Ezzelle J , Rodriguez-ChavezIR, DardenJMet al. Guidelines on good clinical laboratory practice: bridging operations between research and clinical research laboratories. J. Pharm. Biomed. Anal.46(1), 18–29 (2008).
   PubMed Web of Science ®Google Scholar
• King LE , FarleyE, ImazatoMet al. Ligand binding assay critical reagents and their stability: recommendations and best practices from the global bioanalysis consortium harmonization team. AAPS J.16(3), 504–515 (2014).
   PubMed Web of Science ®Google Scholar
• DeSilva B , GarofoloF, RocciMet al. 2012 White Paper on recent issues in bioanalysis and alignment of multiple guidelines. Bioanalysis4(18), 2213–2226 (2012).
   PubMed Web of Science ®Google Scholar
• Stevenson L , RocciM, GarofoloFet al. 2013 White Paper on recent issues in bioanalysis: “hybrid” – the best of LBA & LC/MS. Bioanalysis5(23), 2903–2918 (2013).
   PubMed Web of Science ®Google Scholar
• Stevenson LF , PurushothamaS. Parallelism: considerations for the development, validation and implementation of PK and biomarker ligand-binding assays. Bioanalysis6(2), 185–198 (2014).
   PubMed Web of Science ®Google Scholar
• Mehta D , PurushothamaS, StevensonL. Parallelism: the foundation of biomarker assay development and validation. Bioanalysis10(12), 897–899 (2018).
   PubMed Web of Science ®Google Scholar
• King LE . Parallelism experiments in biomarker ligand-binding assays to assess immunological similarity. Bioanalysis8(23), 2387–2391 (2016).
   PubMed Web of Science ®Google Scholar
• Global CRO Council for Bioanalysis. www.global-cro-council.org
   Google Scholar